Akero Therapeutics Future Growth

Future criteria checks 0/6

Akero Therapeutics is forecast to grow earnings and revenue by 6.4% and 72.4% per annum respectively. EPS is expected to grow by 11.6% per annum. Return on equity is forecast to be -186.1% in 3 years.

Key information

6.4%

Earnings growth rate

11.6%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	72.4%
Future return on equity	-186.1%
Analyst coverage	Good
Last updated	12 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:0K4 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36	-338	-309	-303	4
12/31/2025	N/A	-320	-291	-257	5
12/31/2024	N/A	-265	-189	-161	5
9/30/2024	N/A	-237	-213	-212	N/A
6/30/2024	N/A	-204	-192	-191	N/A
3/31/2024	N/A	-179	-156	-156	N/A
12/31/2023	N/A	-152	-145	-145	N/A
9/30/2023	N/A	-120	-122	-122	N/A
6/30/2023	N/A	-116	-97	-97	N/A
3/31/2023	N/A	-112	-94	-94	N/A
12/31/2022	N/A	-112	-93	-93	N/A
9/30/2022	N/A	-121	-94	-94	N/A
6/30/2022	N/A	-110	-84	-84	N/A
3/31/2022	N/A	-112	-84	-84	N/A
12/31/2021	N/A	-101	-80	-80	N/A
9/30/2021	N/A	-98	-76	-76	N/A
6/30/2021	N/A	-95	-75	-75	N/A
3/31/2021	N/A	-82	-78	-78	N/A
12/31/2020	N/A	-79	-71	-71	N/A
9/30/2020	N/A	-65	-59	-59	N/A
6/30/2020	N/A	-59	-59	-59	N/A
3/31/2020	N/A	-50	-41	-41	N/A
12/31/2019	N/A	-44	-36	-36	N/A
9/30/2019	N/A	-90	-26	-26	N/A
6/30/2019	N/A	-86	-15	-15	N/A
3/31/2019	N/A	-87	-15	-10	N/A
12/31/2018	N/A	-82	-10	-5	N/A
9/30/2018	N/A	-22	-9	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0K4 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0K4 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0K4 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0K4 is forecast to have no revenue next year.

High Growth Revenue: 0K4 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0K4 is forecast to be unprofitable in 3 years.

Akero Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

New major risk - Revenue and earnings growth

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

Co-Founder recently sold €404k worth of stock

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New minor risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold €1.9m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

Independent Director recently sold €1.1m worth of stock

Independent Director recently sold €12m worth of stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

High number of new directors

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients

New 90-day high: €27.80

Akero Therapeutics, Inc. Initiates Phase 2B Harmony Study of Efruxifermin (Efx) for the Treatment of NASH

New 90-day high: €27.00

New 90-day high: €25.00

New 90-day low: €20.20

New 90-day low: €20.60

Akero Therapeutics, Inc. Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

New 90-day low: €23.80

Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients in Ongoing Balanced Study

Akero Therapeutics to Present Data from Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk at The Liver Meeting® 2020

New 90-day low: €26.20

Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $188.213976 million.

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Microcap Value Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies